Indications

Prescribing Information

Next Page Icon

Medication Guide

Next Page Icon
Potential OPDIVO® (nivolumab) user talking to his grandson beside a lake.
Potential OPDIVO® (nivolumab) user talking to his grandson beside a lake.

Clinical trial results for
advanced non-small cell
lung cancer (NSCLC)

For adults with advanced non-small cell lung cancer (NSCLC)

Actor portrayals.
OPDIVO + YERVOY is not approved for people 
younger than 18 years of age.

An FDA-approved combination of two immunotherapies with limited chemotherapy that helped people live longer compared to platinum-based chemotherapyr

About the clinical trial

In a clinical trial of 719 people with previously untreated NSCLC, 361 people were given OPDIVO + YERVOY and platinum-based chemotherapy, and 358 people were given platinum-based chemotherapy.

People given OPDIVO + YERVOY and limited chemotherapy lived longer compared to platinum-based chemotherapy

At 14 months, half the people given OPDIVO® + YERVOY® and platinum-based chemotherapy were alive.
OPDIVO + YERVOY and
platinum-based chemotherapy

Half the people were alive

At 11 months, half the people given only platinum-based chemotherapy were alive.
Platinum-based chemotherapy 

Half the people were alive

In the primary analysis with a minimum follow-up of 8 months, people given OPDIVO + YERVOY and platinum-based chemotherapy had a 31% lower risk of dying than those given platinum-based chemotherapy.

More people given OPDIVO + YERVOY and limited chemotherapy
saw their tumors shrink compared to platinum-based chemotherapy

38% of patients given OPDIVO® + YERVOY® and limited chemotherapy saw tumors shrink, compared to 25% with just chemotherapy.

In an analysis with a minimum follow-up of 7 months, half of the people given OPDIVO + YERVOY and platinum-based chemotherapy lived 7 months without their tumors worsening compared to 5 months for people given platinum-based chemotherapy.

OPDIVO + YERVOY and platinum-based chemotherapy will not work for everyone. Individual results may vary.

Hands exploring how OPDIVO® (nivolumab) works and learning how this treatment may help fight cancer.

How treatment works

See how this treatment may help your body fight cancer

OPDIVO® (nivolumab) side effects.

Side effects

View side effects of treatment and learn how to manage them

Nurse monitoring a gentleman's infusion of OPDIVO® (nivolumab) immunotherapy treatment.

Getting an infusion

See your recommended treatment plan and what to expect from an infusion

For certain adults with advanced non-small cell lung cancer (NSCLC)

OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) and 2 cycles of chemotherapy that contains platinum and another chemotherapy medicine, as a first treatment for adults with a type of advanced stage lung cancer (called non-small cell lung cancer) when your lung cancer has spread or grown, or comes back, and your tumor does not have an abnormal EGFR or ALK gene.

It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.

It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.

OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.



1506-US-2400468 09/24